drugset / Trial / NCT05711810

Medicine-induced Cardiac Hemodialysis on COVID-19

NCT05711810

Phase 4 Completed 1 enrolled Yang I. Pachankis
NaSingle-groupOpen-labelBasic science

Summary

The clinical trial studies the human pathogen of SARS-CoV-2, with a specificity in the circulating Spike 2 protein in the human system. The clinical trial hypothesizes that SARS-CoV-2 human pathogen arises from immune attacks, underlying the severe physiological symptoms that can be lethal. It further hypothesizes that the vaccines do not deal with the Spike 2 protein that causes the immune attacks.

Timeline

Start
2023-01-02
Primary completion
2023-01-10
Completion
2023-01-12

Publications

Drugs

EvaluationDrugModalityDoseRoute
Subject Enalapril Other / unclassified 20 mg Oral
Subject Lansoprazole Other / unclassified 30 mg Oral
Subject Metoprolol Other / unclassified 23.75 mg Oral
Subject Metoprolol Other / unclassified 95 mg Oral
Subject Nifedipine Other / unclassified 30 mg Oral
Subject ORGOTEIN Protein / enzyme biologic Oral